A Comparative Analysis of SG&A Expenses: GSK plc vs Viatris Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Viatris Inc. from 2014 to 2023. Over this period, GSK consistently outspent Viatris, with its SG&A expenses peaking in 2019 at approximately 11.4 billion USD, a 38% increase from 2014. In contrast, Viatris saw a more dramatic rise, with expenses tripling from 1.5 billion USD in 2014 to 4.65 billion USD in 2023. This surge reflects Viatris's strategic investments and expansion efforts. The data highlights the contrasting financial strategies of these pharmaceutical giants, offering insights into their operational priorities and market positioning. As the industry faces new challenges, these trends provide a window into the future financial maneuvers of GSK and Viatris.